Gelsomina Iovane

Gelsomina Iovane

Auto-generated profile, based on publicly available information

Gelsomina Iovane

Progetto ONCONET2.0, Linea Progettuale 14 per l'Implementazione della Prevenzione e Diagnosi Precoce del Tumore alla Prostata e Testicolo, Regione Campania, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
MMMicaela Montanari
Micaela Montanari
SRSABRINA ROSSETTI
SABRINA ROSSETTI
CCCarla Cavaliere
Carla Cavaliere
CDCarmine D’aNiello
Carmine D’aNiello
MMMaria Gabriella Malzone
Maria Gabriella Malzone
GFGAETANO FACCHINI
GAETANO FACCHINI
Epithelial-mesenchymal transition in prostate cancer: an overview

7 April 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
DVDaniela Vanacore
Daniela Vanacore
Mariarosaria BoccellinoMariarosaria Boccellino
Mariarosaria Boccellino
SRSABRINA ROSSETTI
SABRINA ROSSETTI
CCCarla Cavaliere
Carla Cavaliere
CDCarmine D’aNiello
Carmine D’aNiello
GFGAETANO FACCHINI
GAETANO FACCHINI
Micrornas in prostate cancer: an overview

18 September 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
Mariarosaria BoccellinoMariarosaria Boccellino
Mariarosaria Boccellino
DVDaniela Vanacore
Daniela Vanacore
SZSilvia Zappavigna
Silvia Zappavigna
CCCarla Cavaliere
Carla Cavaliere
SRSABRINA ROSSETTI
SABRINA ROSSETTI
GFGAETANO FACCHINI
GAETANO FACCHINI
Testicular cancer from diagnosis to epigenetic factors Testicular cancer from diagnosis to epigenetic factors

30 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
Vincenzo QuagliarielloVincenzo Quagliariello
Vincenzo Quagliariello
SRSABRINA ROSSETTI
SABRINA ROSSETTI
CCCarla Cavaliere
Carla Cavaliere
RPRossella Di Palo
Rossella Di Palo
ELElvira Lamantia
Elvira Lamantia
GFGAETANO FACCHINI
GAETANO FACCHINI
This review summarizes the main pathophysiological basis of the relationship between metabolic syndrome, endocrine disruptor exposure and prostate cancer that is the most common cancer among men in industrialized countries. Metabolic syndrome is a cluster of metabolic and hormonal factors having a central role in the initiation and recurrence of many western chronic diseases including hormonal-related cancers and it is considered as the world’s leading health problem in the coming years. Many biological factors correlate metabolic syndrome to prostate cancer and this review is aimed to focus, principally, on growth factors, cytokines, adipokines, central obesity, endocrine abnormalities and exposure to specific endocrine disruptors, a cluster of chemicals, to which we are daily exposed, with a hormone-like structure influencing oncogenes, tumor suppressors and proteins with a key role in metabolism, cell survival and chemo-resistance of prostate cancer cells. Finally, this review will analyze, from a molecular point of view, how specific foods could reduce the relative risk of incidence and recurrence of prostate cancer or inhibit the biological effects of endocrine disruptors on prostate cancer cells. On the basis of these considerations, prostate cancer remains a great health problem in terms of incidence and prevalence and interventional studies based on the treatment of metabolic syndrome in cancer patients, minimizing exposure to endocrine disruptors, could be a key point in the overall management of this disease.

18 May 2016 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
GFGAETANO FACCHINI
GAETANO FACCHINI
Orazio CaffoOrazio Caffo
Orazio Caffo
COCinzia Ortega
Cinzia Ortega
CDCarmine D'Aniello
Carmine D'Aniello
MNMarilena Di Napoli
Marilena Di Napoli
CCCarlo Cavaliere
Carlo Cavaliere
BACKGROUND Abiraterone Acetate (AA) is approved for the treatment of mCRPC after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated and for treatment of mCRPC progressed during or after docetaxel-based chemotherapy regimen. The aim of this study is to evaluate the role of early PSA decline for detection of therapy success or failure in mCRPC patients treated with AA in post chemotherapy setting. PATIENTS AND METHODS We retrospectively evaluated 87 patients with mCRPC treated with AA. Serum PSA levels were evaluated after 15, 90 days and then monthly. The PSA flare phenomenon was evaluated, according to a confirmation value at least one week apart. The primary endpoint was to demonstrate that an early PSA decline correlates with a longer progression free survival (PFS) and overall survival (OS). The secondary endpoind was to demonstrate a correlation between better outcome and demographic and clinical patient characteristics. RESULTS We have collected data of 87 patients between Sep 2011 and Sep 2014. Early PSA response (≥ 50% from baseline at 15 days) was found in 56% evaluated patients and confirmed in 29 patients after 90 days. The median progression free survival (PFS) was 5,5 months (4,6-6,5) and the median overall survival (OS) was 17,1 months (8,8-25,2). In early responders patients (PSA RR ≥ 50% at 15 days), we found a significant statistical advantage in terms of PFS at 1 year, HR 0.28, 95%CI 0.12-0.65, p=0.003, and OS, HR 0.21 95% CI 0.06-0.72, p=0.01. The results in PFS at 1 years and OS reached statistical significance also in the evaluation at 90 days. CONCLUSION A significant proportion (78.6%) of patients achieved a rapid response in terms of PSA decline. Early PSA RR (≥ 50% at 15 days after start of AA) can provide clinically meaningful information and can be considered a surrogate of longer PFS and OS.

5 December 2017 in The Neuroradiology Journal
Verified
Journal Article
Closed access
RFROSSELLA DI FRANCO
ROSSELLA DI FRANCO
VBValentina Borzillo
Valentina Borzillo
VRVincenzo Ravo
Vincenzo Ravo
SFSara Falivene
Sara Falivene
FRFrancesco Jacopo Romano
Francesco Jacopo Romano
PMPaolo Muto
Paolo Muto
Objective: The aim of this work was to evaluate the impact of stereotactic radiosurgery/fractionated stereotactic radiotherapy with the Cyberknife system on local disease control, clinical outcome and toxicity in patients with meningioma, according to the site and histological grade of lesion. From January 2013 to April 2017, 52 patients with intracranial meningiomas were treated with the Cyberknife system. Twenty-four patients had undergone previous surgery: 38% gross total resection, 10% subtotal resection; 27 patients underwent no surgery; 22 patients had a recurrence of meningioma. Methods: Radiosurgery was used for lesions smaller than 2 cm, stereotactic radiotherapy for lesions larger than 2 cm, or smaller but close to a critical site such as the optical chiasm, optic pathway or brainstem. Results: Local control and clinical outcomes were analysed. Median follow-up was 20 months: six patients died, one after re-surgery died from post-surgical sepsis, three from heart disease. Progression-free survival had a mean value of 38.3 months and overall survival of 41.6 months. We evaluated at 12 months 28 patients (100% local control); at 24 months 19 patients (89% local control); at 36 months nine patients (89% local control). At baseline, 44/52 patients (85%) were symptomatic: 19 visual disorders, 17 motor disorders, six hearing disorders, 10 headache and six epilepsy. Visual symptoms remained unchanged in 52%, improved in 32%, resolved in 16%. Headache was improved in 40%, resolved in 10%, unchanged in 50%. Epilepsy was resolved in 17%, unchanged in 33%, worsened in 33%. Conclusions: Stereotactic radiosurgery/fractionated stereotactic radiotherapy with Cyberknife provides a good local disease control, improving visual, hearing and motor symptoms.